NASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Price, News & Analysis $1.58 -0.09 (-5.39%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About VYNE Therapeutics Stock (NASDAQ:VYNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VYNE Therapeutics alerts:Sign Up Key Stats Today's Range$1.54▼$1.6450-Day Range$1.53▼$2.8052-Week Range$1.53▼$4.30Volume90,195 shsAverage Volume85,026 shsMarket Capitalization$24.03 millionP/E RatioN/ADividend YieldN/APrice Target$6.88Consensus RatingBuy Company OverviewVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Read More… Remove Ads VYNE Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreVYNE MarketRank™: VYNE Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 498th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VYNE Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VYNE Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.19% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently increased by 21.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.19% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently increased by 21.57%, indicating that investor sentiment is decreasing significantly. News and Social Media1.0 / 5News Sentiment-0.14 News SentimentVYNE Therapeutics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VYNE Therapeutics this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $43,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by Institutions83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VYNE Therapeutics' insider trading history. Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNE Stock News HeadlinesVYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Increase in Short InterestApril 2 at 2:59 AM | americanbankingnews.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.April 4, 2025 | Colonial Metals (Ad)VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)March 12, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)March 7, 2025 | markets.businessinsider.comVYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2025 | finance.yahoo.comVYNE Therapeutics reports Q4 EPS (28c) vs (20c) last yearMarch 6, 2025 | markets.businessinsider.comSee More Headlines VYNE Stock Analysis - Frequently Asked Questions How have VYNE shares performed this year? VYNE Therapeutics' stock was trading at $3.35 on January 1st, 2025. Since then, VYNE shares have decreased by 51.2% and is now trading at $1.6350. View the best growth stocks for 2025 here. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) released its quarterly earnings data on Thursday, March, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.14 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative trailing twelve-month return on equity of 43.73%. When did VYNE Therapeutics' stock split? VYNE Therapeutics's stock reverse split on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA). Company Calendar Last Earnings3/06/2025Today4/04/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VYNE CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$6.88 High Stock Price Target$8.00 Low Stock Price Target$5.75 Potential Upside/Downside+320.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,450,000.00 Net Margins-6,896.55% Pretax Margin-6,885.19% Return on Equity-43.73% Return on Assets-38.55% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$501,000.00 Price / Sales49.64 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.26Miscellaneous Outstanding Shares15,210,000Free Float14,043,000Market Cap$24.87 million OptionableNot Optionable Beta1.37 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:VYNE) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.